Clinical and economic analysis of the use of drugs in the treatment of Parkinson’s Disease
DOI:
https://doi.org/10.17308/meps/2078-9017/2026/8/108-122Keywords:
pharmacoeconomic analysis, cost-utility, cost of illness, performance indicators, medical institutionsAbstract
Importance: сlinical and economic aspects of treating patients with Parkinson’s disease, in particular, the structure and dynamics of direct medical costs depending on the stage of the disease, quality of life of patients with different treatment regimens, the ratio of costs and clinical benefit. Purpose: to evaluate the economic effectiveness of drug therapy for Parkinson’s disease using the methods of clinical and economic analysis “cost of disease” and “cost-utility” depending on the stage of the disease, to determine the optimal treatment regimens taking into account costeffectiveness. Research design: retrospective analysis of clinical and anamnestic data of patients of the Budgetary Healthcare Institution of the VO “Voronezh Regional Clinical Hospital No. 1”; assessment of direct medical costs of drug therapy using current retail prices of drugs, the inclusion criterion is a verified diagnosis of Parkinson’s disease with determination of the stage according to the Hoehn and Yahr scale. Results: a direct correlation was found between the cost of annual therapy and the cost of achieving one “quality year of life”; the need for early initiation of therapy to optimize the cost-utility ratio was confirmed. The feasibility of a differentiated approach to financing the treatment of patients with different stages of Parkinson’s disease is substantiated; the data analyzed by the authors can be used to predict the burden on the healthcare system, optimize treatment regimens taking into account the cost-utility ratio, and plan budgets depending on the stage of Parkinson’s disease.
References
1. Белоусов Д.Ю., Афанасьева Е.В. Фармакоэкономический анализ применения прамипексола пролонгированного действия в режиме монотерапии на ранних стадиях болезни Паркинсона // Качественная клиническая практика, 2015, no. 1.
2. Вартанов С.А., Богатова И.Э., Денисова И.А., Кучеряну В.Г., Турдыева Н.А., Чубарова Т.В., Шаклеина М.В., Полтерович В.М. Экономическая эффективность доклинической диагностики болезни Паркинсона: Марковская модель // Вестник ТГЭУ, 2020, no. 4 (96).
3. Головин С.В. Осуществление контроля в сфере закупок в государственных медицинских организациях // Современная экономика: проблемы и решения, 2018, no. 4 (100), с. 95-103.
4. Коробейникова Л.С., Панина И.В. Формирование и анализ отчетной информации о сегментах деятельности организации // Экономический анализ: теория и практика, 2014, no. 13 (364), с. 39-48.
5. Полухина И.В., Разуваев Г.А. Структурно-динамический анализ активов бюджетного учреждения здравоохранения // Современная экономика: проблемы и решения, 2025, no. 12 (192), с. 108-121.
6. Разуваев Г.А. Экономический анализ демографических характеристик пациентов с болезнью Паркинсона // Апрельские научные чтения имени профессора Л.Т. Гиляровской: Сборник научных статей XV Международной научно-практической конференции, Воронеж, 2026, т. II, с. 204-208.
7. Рудакова А.В., Левин О.С. Фармакоэкономические аспекты комбинированной терапии развернутой стадии болезни Паркинсона // Нервные болезни, 2017, no. 2.
8. Ендовицкий Д.А., Сапожникова Н.Г., Коробейникова Л.С. и др. Учет, анализ и контроль в государственном здравоохранении. Воронеж, Издательский дом ВГУ, 2021. 144 с.
9. Dams J., Zapp J.J., König H.H. Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: An Updated Methodological Review // Pharmacoeconomics, 2023, vol. 41, no. 10, pp. 1205-1228.
10. Evans D., Mistry C., Knight H., et al. Inhaled Levodopa for the Management of OFF Episodes in Parkinson’s Disease: A Cost-Effectiveness Analysis // PharmacoEconomics, 2026.
11. Harrison-Jones G., Green W., Bainbridge J. The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson’s Disease Experiencing Endof-Dose Motor Fluctuations // Parkinson’s Disease, 2025, no. 8408907. 12 p.
12. Johnson S.J., Diener M.D., Kaltenboeck A., Birnbaum H.G., Siderowf A.D. An economic model of Parkinson’s disease: implications for slowing progression in the United States // Movement Disorders, 2013, vol. 28, no. 3, pp. 319-326.
13. Siderowf A., Ravina B., Glick H.A. Preference-based quality-of-life in patients with Parkinson’s disease // Neurology, 2002, vol. 59, no. 1, pp. 103-10
